Document is current

Any future updates will be listed below

Tisotumab-Vedotin: wirksame Option in Zweit- oder Drittlinie

Crossref DOI link: https://doi.org/10.1007/s15004-024-0771-2

Published Online: 2024-11-21

Published Print: 2024-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark